Journal of Clinical Endocrinology & Metabolism, Vol 72, 1130-1135, Copyright © 1991 by Endocrine Society

ARTICLES

Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism

MA Jacobson, JG Gambertoglio, FT Aweeka, DM Causey and AA Portale
Department of Medicine, University of California, San Francisco 94143.

Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia. To further elucidate the magnitude and mechanism of these abnormalities in humans treated with foscarnet for opportunistic herpes virus infections, we analyzed anaerobic serum specimens and 24-h urine samples before and after single and multiple doses of iv foscarnet and performed a series of in vitro experiments with normal human serum and plasma. Plasma ionized calcium concentrations acutely decreased by a mean 0.17 mmol/L in the 6 individuals who received a 90 mg/kg dose of foscarnet and by a mean 0.28 mmol/L in the 11 individuals who received a 120 mg/kg dose (P = 0.016, 90 vs. 120 mg/kg dose). Results of in vitro experiments showed a highly significant inverse linear relationship between foscarnet and ionized calcium concentrations, but no correlation between foscarnet and total calcium or phosphate concentration. Dialysis experiments suggested that the complexing of foscarnet with ionized calcium could be a cause of this ionized hypocalcemia. Physicians must be aware of this phenomenon and should measure serum ionized calcium during foscarnet therapy (preferably at the end of a foscarnet infusion) whenever neurological or cardiological abnormalities occur.

This article has been cited by other articles:

				M. M. Huycke, M. T. Naguib, M. M. Stroemmel, K. Blick, K. Monti, S. Martin-Munley, and C. Kaufman A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2143 - 2148. [Abstract] [Full Text]

				J. G. Jacobson, T. E. Renau, M. R. Nassiri, D. G. Sweier, J. M. Breitenbach, L. B. Townsend, and J. C. Drach Nonnucleoside Pyrrolopyrimidines with a Unique Mechanism of Action against Human Cytomegalovirus Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1888 - 1894. [Abstract] [Full Text]

				M. A. Jacobson Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., July 10, 1997; 337(2): 105 - 114. [Full Text] [PDF]